Diametric Capital, LP Aerie Pharmaceuticals Inc Transaction History

Diametric Capital, LP

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	BUY	$6.37 - $15.23 $118,310 - $282,866	18,573 New	18,573 $281,000
Q3 2020 Nov 13, 2020	SELL	$10.46 - $14.46 $227,599 - $314,635	-21,759 Closed	0 $0
Q2 2020 Aug 14, 2020	BUY	$12.0 - $16.13 $49,404 - $66,407	4,117 Added 23.34%	21,759 $321,000
Q1 2020 May 15, 2020	SELL	$11.84 - $25.52 $174,225 - $375,526	-14,715 Reduced 45.48%	17,642 $238,000
Q4 2019 Feb 14, 2020	BUY	$17.72 - $25.1 $573,366 - $812,160	32,357 New	32,357 $782,000
Q2 2019 Aug 14, 2019	SELL	$28.97 - $48.21 $170,140 - $283,137	-5,873 Closed	0 $0
Q1 2019 May 15, 2019	BUY	$36.32 - $49.25 $213,307 - $289,245	5,873 New	5,873 $279,000
Q3 2018 Nov 14, 2018	SELL	$56.15 - $73.9 $1.66 Million - $2.19 Million	-29,629 Closed	0 $0
Q2 2018 Aug 14, 2018	BUY	$47.85 - $70.45 $198,912 - $292,860	4,157 Added 16.32%	29,629 $2 Million
Q1 2018 May 15, 2018	BUY	$51.15 - $61.0 $942,131 - $1.12 Million	18,419 Added 261.15%	25,472 $1.38 Million
Q4 2017 Feb 14, 2018	BUY	$50.85 - $65.1 $358,645 - $459,150	7,053	7,053 $421,000

2.4M

Ticker AERI
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 49,390,500
Description
Aerie Pharmaceuticals, Inc., a pharmaceutical company, focuses on the discovery, development, and commercialization of ophthalmic therapies for open-angle glaucoma, dry eye, diabetic macular edema, and wet age-related macular degeneration in the United States. Its products include Rhopressa, a once-daily eye drop to reduce elevated intraocular p...

Get notified when there are updates to the investment portfolio of Diametric Capital, LP, based on Form 13F filings with the SEC.

Stay updated on Diametric Capital, LP with notifications on news.